1. Tipifarnib and bortezomib are synergistic in cytotoxicity assays
Tipifarnib and bortezomib are synergistic in cytotoxicity assays. 8226/S (A) and U937 (B) cells were treated with tipifarnib, bortezomib, or a constant molar ratio (100:1) of the combination for 72 hours.
Tipifarnib and bortezomib are synergistic in cytotoxicity assays. 8226/S (A) and U937 (B) cells were treated with tipifarnib, bortezomib, or a constant molar ratio (100:1) of the combination for 72 hours. Cytotoxicity was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays (as described in Materials and Methods). The resulting data was used to generate combination index plots (CI) for various dose combinations. The dashed line indicates additive affect (CI = 1). Antagonism (above dashed line) and synergism (below dashed line). Tables are included to provide the drug concentrations tested. Points, average of quadruplicate values of three independent experiments; bars, SD.
Niranjan Yanamandra et al. Clin Cancer Res 2006;12:
©2006 by American Association for Cancer Research